SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dave, R. H.
Right arrow Articles by Kloner, R. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dave, R. H.
Right arrow Articles by Kloner, R. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Effect of Melatonin on Hemodynamics, Blood Flow, and Myocardial Infarct Size in a Rabbit Model of Ischemia-Reperfusion

Ravi H. Dave

Heart Institute of Good Samaritan Hospital, and the Division of Cardiology, University of Southern California, Los Angeles, California

Sharon L. Hale

Heart Institute of Good Samaritan Hospital, and the Division of Cardiology, University of Southern California, Los Angeles, California

Robert A. Kloner

Heart Institute of Good Samaritan Hospital, and the Division of Cardiology, University of Southern California, Los Angeles, California

Background: Melatonin, a hormone, has gained popularity and is being used by millions for a variety of indications. There are few data on its safety or its effects on hemodynamics and coronary blood flow. Also, studies have confirmed that melatonin is a potent antioxidant. Therefore, it may be capable of scavenging free radicals during the reperfusion phase after a heart attack. This study evaluates the safety of melatonin with regard to its cardiovascular effects and tests the hypothesis that melatonin might be protective in the setting of ischemia-reperfusion and reduce myocardial infarct size.

Methods and Results: Anesthetized rabbits were treated with melatonin (n = 8, 10 mg/kg, intravenously) 10 minutes before coronary artery occlusion (CAO) and again 15 minutes before reperfusion. Control rabbits received vehicle (n = 8). All rabbits underwent 30 min utes of occlusion and 3 hour reperfusion. Both before and during CAO, melatonin did not alter heart rate compared with control (185 ± 7 beats/min v 181 ± 7 before; and 179 ± 5 v 181 ± 9 during, respectively, P = NS) or blood pressure (70 ± 4 mmHg v 66 ± 6 before and 59 ± 4 v 58 ± 5 during, respectively, P = NS). Regional myocardial blood flow (RMBF) was similar before CAO in the melatonin group (1.18 ± 0.17 mL/min/g) versus the control group (1.15 ± 0.10 mL/min/g). Infarct size, expressed as a fraction of ischemic risk zone, was simi lar in the melatonin (0.29 ± 0.03) and control groups (0.29 ± 0.06, P = NS). At a higher dose of 50 mg/kg in treated (n = 7) versus control (n = 7) rabbits, melatonin treatment did not alter heart rate (204 ± 14 in melatonin group v 181 ± 5 in controls, P = NS) or blood pressure (80 ± 11 in melatonin v 66 ± 7 in controls, P = NS) when compared with control. Melatonin at this dose also did not affect infarct size, 0.38 ± 0.06, when compared with con trol, 0.34 ± 0.07, P = NS.

Conclusion: Melatonin's effects on hemodynamics and coronary blood flow were neutral, and it did not exacerbate myocardial ischemia or necrosis in this model. Melatonin appears to be a safe drug with no apparent effects on the cardiovascular system in this model.

Key Words: myocardial infarction • antioxidants • free radical scavenger • drug.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 3, No. 2, 153-159 (1998)
DOI: 10.1177/107424849800300208


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
R. J. Reiter and D.-X. Tan
Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart
Cardiovasc Res, April 1, 2003; 58(1): 10 - 19.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
Z. Pei, S. F. Pang, and R. T. F. Cheung
Administration of Melatonin After Onset of Ischemia Reduces the Volume of Cerebral Infarction in a Rat Middle Cerebral Artery Occlusion Stroke Model
Stroke, March 1, 2003; 34(3): 770 - 775.
[Abstract] [Full Text] [PDF]



Advertisement